Trial Outcomes & Findings for Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation. (NCT NCT06581094)
NCT ID: NCT06581094
Last Updated: 2026-01-07
Results Overview
Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain. Explain to the subjects that the pain intensity increases from left to right. Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark. Record the points that the subjects wrote.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
32 participants
Primary outcome timeframe
baseline, week 6, week 12
Results posted on
2026-01-07
Participant Flow
Participants were recruited from social media between August 2024 and September 2024.
Of 32 enrolled participants, all of them met inclusion of criteria, but 2 of them were not included in the analysis because lost of follow-up.
Participant milestones
| Measure |
Control Group
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
Overall Study
STARTED
|
16
|
16
|
|
Overall Study
COMPLETED
|
15
|
15
|
|
Overall Study
NOT COMPLETED
|
1
|
1
|
Reasons for withdrawal
| Measure |
Control Group
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
1
|
Baseline Characteristics
Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation.
Baseline characteristics by cohort
| Measure |
Control Group
n=15 Participants
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
n=15 Participants
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
Total
n=30 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=37 Participants
|
15 Participants
n=56 Participants
|
29 Participants
n=95 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
1 Participants
n=95 Participants
|
|
Age, Continuous
|
33.8 years
STANDARD_DEVIATION 16.65 • n=37 Participants
|
34.8 years
STANDARD_DEVIATION 16.45 • n=56 Participants
|
34.3 years
STANDARD_DEVIATION 16.27 • n=95 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=37 Participants
|
11 Participants
n=56 Participants
|
21 Participants
n=95 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=37 Participants
|
4 Participants
n=56 Participants
|
9 Participants
n=95 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Asian
|
15 Participants
n=37 Participants
|
15 Participants
n=56 Participants
|
30 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=37 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=95 Participants
|
|
Region of Enrollment
Taiwan
|
15 Participants
n=37 Participants
|
15 Participants
n=56 Participants
|
30 Participants
n=95 Participants
|
PRIMARY outcome
Timeframe: baseline, week 6, week 12Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain. Explain to the subjects that the pain intensity increases from left to right. Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark. Record the points that the subjects wrote.
Outcome measures
| Measure |
Control Group
n=15 Participants
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
n=15 Participants
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
Points Change of Pain Evaluation Scale
Normal walk, Right Week 12
|
0.84 score on a scale
Standard Deviation 1.00
|
0.63 score on a scale
Standard Deviation 0.74
|
|
Points Change of Pain Evaluation Scale
Stand up/squat down, Left Baseline
|
2.83 score on a scale
Standard Deviation 1.68
|
2.53 score on a scale
Standard Deviation 1.61
|
|
Points Change of Pain Evaluation Scale
Stand up/squat down, Right Week 12
|
1.51 score on a scale
Standard Deviation 1.35
|
1.20 score on a scale
Standard Deviation 1.09
|
|
Points Change of Pain Evaluation Scale
Bend to biggest angle, Left Baseline
|
2.53 score on a scale
Standard Deviation 2.22
|
1.50 score on a scale
Standard Deviation 1.18
|
|
Points Change of Pain Evaluation Scale
Bend to biggest angle, Left Week 6
|
1.54 score on a scale
Standard Deviation 1.50
|
1.23 score on a scale
Standard Deviation 1.47
|
|
Points Change of Pain Evaluation Scale
Normal walk, Left Baseline
|
1.49 score on a scale
Standard Deviation 1.19
|
1.15 score on a scale
Standard Deviation 0.94
|
|
Points Change of Pain Evaluation Scale
Normal walk, Left Week 6
|
1.15 score on a scale
Standard Deviation 1.13
|
1.14 score on a scale
Standard Deviation 1.08
|
|
Points Change of Pain Evaluation Scale
Normal walk, Left Week 12
|
0.85 score on a scale
Standard Deviation 1.05
|
0.50 score on a scale
Standard Deviation 0.75
|
|
Points Change of Pain Evaluation Scale
Normal walk, Right Baseline
|
1.49 score on a scale
Standard Deviation 1.19
|
1.15 score on a scale
Standard Deviation 0.94
|
|
Points Change of Pain Evaluation Scale
Normal walk, Right Week 6
|
1.29 score on a scale
Standard Deviation 1.47
|
1.31 score on a scale
Standard Deviation 1.10
|
|
Points Change of Pain Evaluation Scale
Stand up/squat down, Left Week 6
|
1.81 score on a scale
Standard Deviation 1.39
|
1.67 score on a scale
Standard Deviation 1.22
|
|
Points Change of Pain Evaluation Scale
Stand up/squat down, Left Week 12
|
1.29 score on a scale
Standard Deviation 1.29
|
0.97 score on a scale
Standard Deviation 0.85
|
|
Points Change of Pain Evaluation Scale
Stand up/squat down, Right Baseline
|
2.83 score on a scale
Standard Deviation 1.68
|
2.53 score on a scale
Standard Deviation 1.61
|
|
Points Change of Pain Evaluation Scale
Stand up/squat down, Right Week 6
|
2.04 score on a scale
Standard Deviation 1.72
|
1.78 score on a scale
Standard Deviation 1.42
|
|
Points Change of Pain Evaluation Scale
Bend to biggest angle, Left Week 12
|
0.98 score on a scale
Standard Deviation 1.12
|
0.52 score on a scale
Standard Deviation 0.53
|
|
Points Change of Pain Evaluation Scale
Bend to biggest angle, Right Baseline
|
2.53 score on a scale
Standard Deviation 2.22
|
1.50 score on a scale
Standard Deviation 1.18
|
|
Points Change of Pain Evaluation Scale
Bend to biggest angle, Right Week 6
|
1.54 score on a scale
Standard Deviation 1.50
|
1.23 score on a scale
Standard Deviation 1.47
|
|
Points Change of Pain Evaluation Scale
Bend to biggest angle, Right Week 12
|
0.98 score on a scale
Standard Deviation 1.12
|
0.52 score on a scale
Standard Deviation 0.53
|
PRIMARY outcome
Timeframe: baseline, week 6, week 12Timed up-and-go test (TUG) was a professional physical therapist marked a distance of 3 meters on the ground and placed an armless chair at one end. The subject sat on the chair with a straight back, and the time was measured from when the subject stood up and walked to the 3-meter mark at their usual speed, turned around, walked back, and sat down again. Shorter time spent indicates better knee function. Record the time that the subjects spent.
Outcome measures
| Measure |
Control Group
n=15 Participants
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
n=15 Participants
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
Time Change of Up-and-go Test
Week 12
|
8.64 unit of measure: seconds
Standard Deviation 0.73
|
8.55 unit of measure: seconds
Standard Deviation 0.76
|
|
Time Change of Up-and-go Test
Baseline
|
9.96 unit of measure: seconds
Standard Deviation 1.47
|
9.3 unit of measure: seconds
Standard Deviation 0.98
|
|
Time Change of Up-and-go Test
Week 6
|
8.75 unit of measure: seconds
Standard Deviation 0.68
|
8.83 unit of measure: seconds
Standard Deviation 0.71
|
PRIMARY outcome
Timeframe: baseline, week 6, week 12A professional physical therapist tested the active flexion and extension of the knee joint (range of motion, ROM) as the subjects attempted to achieve maximum active flexion and extension. Record the angle that the physical therapist measured. AROM: active range of motion; PROM: passive range of motion
Outcome measures
| Measure |
Control Group
n=15 Participants
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
n=15 Participants
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
Degrees Change of Range of Motion (ROM)
AROM, Left Baseline
|
141.73 unit of measure: Degrees
Standard Deviation 6.84
|
137.67 unit of measure: Degrees
Standard Deviation 8.35
|
|
Degrees Change of Range of Motion (ROM)
AROM, Left Week 6
|
141.20 unit of measure: Degrees
Standard Deviation 7.88
|
140.80 unit of measure: Degrees
Standard Deviation 8.54
|
|
Degrees Change of Range of Motion (ROM)
AROM, Left Week 12
|
137.93 unit of measure: Degrees
Standard Deviation 7.66
|
136.80 unit of measure: Degrees
Standard Deviation 11.03
|
|
Degrees Change of Range of Motion (ROM)
AROM, Right Baseline
|
141.20 unit of measure: Degrees
Standard Deviation 6.70
|
138.00 unit of measure: Degrees
Standard Deviation 6.85
|
|
Degrees Change of Range of Motion (ROM)
AROM, Right Week 6
|
140.80 unit of measure: Degrees
Standard Deviation 8.54
|
140.67 unit of measure: Degrees
Standard Deviation 8.57
|
|
Degrees Change of Range of Motion (ROM)
AROM, Right Week 12
|
138.00 unit of measure: Degrees
Standard Deviation 7.78
|
138.67 unit of measure: Degrees
Standard Deviation 8.16
|
|
Degrees Change of Range of Motion (ROM)
PROM, Left Baseline
|
143.20 unit of measure: Degrees
Standard Deviation 7.08
|
139.33 unit of measure: Degrees
Standard Deviation 8.20
|
|
Degrees Change of Range of Motion (ROM)
PROM, Left Week 6
|
143.07 unit of measure: Degrees
Standard Deviation 7.52
|
142.67 unit of measure: Degrees
Standard Deviation 8.27
|
|
Degrees Change of Range of Motion (ROM)
PROM, Left Week 12
|
141.40 unit of measure: Degrees
Standard Deviation 7.67
|
138.80 unit of measure: Degrees
Standard Deviation 11.10
|
|
Degrees Change of Range of Motion (ROM)
PROM, Right Baseline
|
142.40 unit of measure: Degrees
Standard Deviation 6.60
|
139.73 unit of measure: Degrees
Standard Deviation 6.63
|
|
Degrees Change of Range of Motion (ROM)
PROM, Right Week 6
|
142.67 unit of measure: Degrees
Standard Deviation 7.95
|
142.67 unit of measure: Degrees
Standard Deviation 8.30
|
|
Degrees Change of Range of Motion (ROM)
PROM, Right Week 12
|
141.60 unit of measure: Degrees
Standard Deviation 7.14
|
140.13 unit of measure: Degrees
Standard Deviation 8.26
|
PRIMARY outcome
Timeframe: baseline, week 6, week 12Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points). The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points). The higher score meant worse knee joint function. Record the points that the subjects got.
Outcome measures
| Measure |
Control Group
n=15 Participants
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
n=15 Participants
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Pain Baeline
|
5.73 score on a scale
Standard Deviation 2.99
|
5.27 score on a scale
Standard Deviation 2.52
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Pain Week 6
|
4.47 score on a scale
Standard Deviation 2.53
|
4.73 score on a scale
Standard Deviation 2.94
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Pain Week 12
|
4.07 score on a scale
Standard Deviation 2.99
|
3.67 score on a scale
Standard Deviation 2.72
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Stiffness Baseline
|
1.93 score on a scale
Standard Deviation 1.39
|
1.60 score on a scale
Standard Deviation 0.99
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Stiffness Week 6
|
1.13 score on a scale
Standard Deviation 0.92
|
1.53 score on a scale
Standard Deviation 0.92
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Stiffness Week 12
|
1.27 score on a scale
Standard Deviation 1.22
|
1.33 score on a scale
Standard Deviation 0.90
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Physical function Baseline
|
10.00 score on a scale
Standard Deviation 8.64
|
9.00 score on a scale
Standard Deviation 6.28
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Physical function Week 6
|
6.47 score on a scale
Standard Deviation 6.62
|
6.53 score on a scale
Standard Deviation 4.76
|
|
Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Physical function Week 12
|
6.73 score on a scale
Standard Deviation 8.56
|
4.87 score on a scale
Standard Deviation 4.98
|
PRIMARY outcome
Timeframe: baseline, week 6, week 12Population: Data were not reported because the value was lower than limit of detection.
The concentration of interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor alpha (TNF-α) in serum.
Outcome measures
| Measure |
Control Group
n=15 Participants
Control group use 42 mg UCII.
Placebo: Placebo capsules twice daily.
|
Test Group (UCII, Glucosamine, and Curcumin)
n=15 Participants
Test group use 42 mg UCII, 460 mg glucosamine and 380 mg curcumin
UCII, glucosamine and curcumin: compound capsules twice daily.
|
|---|---|---|
|
The Concentration of Serum Inflammatory Factors
TNF-α Week 6
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
IL-1β Week 6
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
IL-1β Week 12
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
TNF-α Baseline
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
IL-6 Baseline
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
IL-6 Week 6
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
IL-6 Week 12
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
IL-1β Baseline
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
|
The Concentration of Serum Inflammatory Factors
TNF-α Week 12
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
NA unit of measure: concentration (pg/mL)
Standard Deviation NA
The data were below the lower limit of quantification.
|
Adverse Events
Control Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Test Group (UCII, Glucosamine, and Curcumin)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place